Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Covington
Baxter
Daiichi Sankyo
US Army
Harvard Business School

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,265,392

« Back to Dashboard

Which drugs does patent 6,265,392 protect, and when does it expire?

Patent 6,265,392 protects CALCIJEX and is included in one NDA.

Protection for CALCIJEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,265,392
Title: Low oxygen content compositions of 1.alpha., 25-dihydroxycholeclciferol
Abstract:The invention relates to stable aqueous formulations comprising 1.alpha.,25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.
Inventor(s): Abrahamson; Kent (Libertyville, IL), Anderson; Amy N. (Waukegan, IL), Grady; Haiyan (Mundelein, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/494,674
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,265,392
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 6,265,392

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie CALCIJEX calcitriol INJECTABLE;INJECTION 018874-001 Sep 25, 1986 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie CALCIJEX calcitriol INJECTABLE;INJECTION 018874-002 Sep 25, 1986 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Chinese Patent Office
Medtronic
Teva
Fuji
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.